EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV

Nicole F Maranchick iD, Charles Martyn-Dickens, Anthony Enimil, Hongmei Yang, Aikins Kofi Amissah, Albert Dompreh, Dennis Bosomtwe, Eugenia Sly-Moore, Theresah Opoku, Augustina Frimpong Appiah, Priscilla Asiedu, Sampson Antwi und 3 weitere

Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)

DOI: 10.1128/aac.00909-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Nicole F Maranchick und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, US…. Hauptthemen laut MEDLINE: Pyrazinamide, Ethambutol, Antitubercular Agents, HIV Infections. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is a major cause of morbidity and mortality in children globally. This study developed models to describe population pharmacokinetics (PK) of pyrazinamide (PZA) and ethambutol (EMB) in children with TB with or without human immunodeficiency virus (HIV) coinfection. Ghanaian children with TB with or without HIV coinfection receiving first-line antituberculosis therapy for at least 4 weeks had blood samples collected at time 0 (pre-dose), 1-, 2-, 4-, 8-, and 12-h post-dose. PZA and EMB concentrations were quantified using liquid chromatography tandem mass spectrometry. Nonlinear mixed-effects models were applied to describe the population PK using Monolix2024R1. Maximum concentrations ( C max ) and 24-h area under the time concentration curve (AUC 0–24 ) were compared to published values in adults. A total of 85 children (41 TB, 44 TB/HIV) were included. The median (range) age was 5 years (0.3–14.5), and 61.2% were male. Median (range) doses for PZA and EMB were 31.6 (21.4–49.7) and 21.4 mg/kg (14.3–34.2), respectively. PZA was best described using a one-compartment model and EMB by a two-compartment model. Allometric scaling improved both model fits. Children with TB/HIV coinfection had approximately 18.5% faster PZA clearance and 25% faster EMB clearance. Optimized dosing to achieve adult-equivalent exposures required higher-than-currently recommended doses, particularly among children in the lowest weight bands and those with HIV. The population PK of PZA and EMB was well described by the final models, but the higher-than-currently recommended doses needed to achieve adult-equivalent exposures raise concerns regarding risks for drug-associated toxicities and will require further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinamideEthambutolAntitubercular AgentsHIV InfectionsTuberculosisHumansMaleChildChild, PreschoolFemaleInfantCoinfectionAdolescentArea Under Curve

Stichwörter der Autor:innen

anti-tuberculosis drugsethambutolpediatricspopulation pharmacokineticspyrazinamide

Substanzen

PyrazinamideEthambutolAntitubercular Agents

Autor:innen und Institutionen

  • Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
  • Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
  • Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
  • Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
  • Department of Clinical Microbiology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
  • Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

ORCID-Profile: Nicole F Maranchick, Marc H Scheetz, Awewura Kwara

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH)

Zitieren

APA

Maranchick, N. F., Martyn-Dickens, C., Enimil, A., Yang, H., Amissah, A. K., Dompreh, A., Bosomtwe, D., Sly-Moore, E., Opoku, T., Frimpong Appiah, A., Asiedu, P., Antwi, S., Scheetz, M. H., Peloquin, C. A., & Kwara, A. (2026). Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.00909-25

Vancouver

Maranchick NF, Martyn-Dickens C, Enimil A, Yang H, Amissah AK, Dompreh A, et al. Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.00909-25

BibTeX
@article{Maranchick2026,
  author = {Maranchick, Nicole F and Martyn-Dickens, Charles and Enimil, Anthony and Yang, Hongmei and Amissah, Aikins Kofi and Dompreh, Albert and Bosomtwe, Dennis and Sly-Moore, Eugenia and Opoku, Theresah and Frimpong Appiah, Augustina and Asiedu, Priscilla and Antwi, Sampson and Scheetz, Marc H and Peloquin, Charles A and Kwara, Awewura},
  title = {Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {4},
  doi = {10.1128/aac.00909-25}
}
Kostenlos starten →